首页 > 最新文献

International Journal of Rheumatic Diseases最新文献

英文 中文
DRESSed for Relapse: A Rare Case of Leflunomide-Induced DRESS With Hepatic Complications 治疗复发:一例罕见的来氟米特诱导的DRESS伴肝脏并发症。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-28 DOI: 10.1111/1756-185x.70560
Kajal Patel, Pooja Jotwani, Marie-Claire Maroun
{"title":"DRESSed for Relapse: A Rare Case of Leflunomide-Induced DRESS With Hepatic Complications","authors":"Kajal Patel, Pooja Jotwani, Marie-Claire Maroun","doi":"10.1111/1756-185x.70560","DOIUrl":"10.1111/1756-185x.70560","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 2","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146063582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Radiographic Factors Associated With Difficult-to-Manage Axial Spondyloarthritis: A Multicenter Study 临床和影像学因素与难以控制的轴型脊柱炎相关:一项多中心研究。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-28 DOI: 10.1111/1756-185x.70558
Haluk Cinakli, Mete Kara, Gülay Alp

Objective

To evaluate the clinical characteristics, disease burden, and treatment patterns of axial spondyloarthritis (axSpA) using the recently proposed Assessment of Spondyloarthritis International Society (ASAS) definition of difficult-to-manage axSpA (D2M-axSpA).

Methods

A total of 383 patients with axSpA were enrolled. This multicenter cross-sectional study was conducted in three tertiary care centers, enrolling consecutive axSpA patients from outpatient clinics. Patients were classified as D2M-axSpA based on prior use of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and persistent disease activity based on the ASAS definition. Logistic regression analysis identified factors associated with D2M-axSpA.

Results

Among patients, 11.2% met the D2M-axSpA criteria. The cohort was 58.7% male, with a mean age of 43.5 ± 10.5 years. Radiographic axSpA was present in 70.8%, and 69.2% of patients had received biological therapy. D2M-axSpA patients exhibited higher inflammatory markers (ESR, CRP), increased disease activity (BASDAI, ASDAS-CRP), and greater functional impairment (BASFI, ASQoL). Peripheral arthritis (p = 0.001), enthesitis (p = 0.031), smoking history (p = 0.037), and comorbidities (p = 0.020) were significantly more frequent in D2M-axSpA. Among D2M-axSpA patients, 22/383 (5.7%) fulfilled the treatment-refractory criteria. Radiographic findings revealed higher rates of sacroiliac ankylosis, lumbar syndesmophytes, symphysitis, and ischial enthesitis, as well as mSASSS scores. Logistic regression identified anterior uveitis (OR: 4.474, p = 0.007), peripheral arthritis (OR: 2.684, p = 0.021), and comorbidities (OR: 2.878, p = 0.013) as independently associated factors.

Conclusion

Findings highlight the clinical and radiographic burden of D2M-axSpA and emphasize the need for optimized treatment strategies, particularly in patients with comorbidities, a history of anterior uveitis or peripheral arthritis, and those with a smoking history.

目的:利用最近提出的国际脊椎关节炎协会(ASAS)对难以控制的轴性脊柱炎(D2M-axSpA)的定义,评估轴性脊柱炎(axSpA)的临床特征、疾病负担和治疗模式。方法:共纳入383例axSpA患者。这项多中心横断面研究在三个三级保健中心进行,从门诊连续招募axSpA患者。根据先前使用生物或靶向合成疾病改善抗风湿药物(b/tsDMARDs)和基于ASAS定义的持续疾病活动,将患者分类为D2M-axSpA。Logistic回归分析确定了与D2M-axSpA相关的因素。结果:11.2%的患者符合D2M-axSpA标准。队列中58.7%为男性,平均年龄43.5±10.5岁。70.8%的患者有放射学axSpA, 69.2%的患者接受了生物治疗。D2M-axSpA患者表现出更高的炎症标志物(ESR, CRP),疾病活动性增加(BASDAI, ASDAS-CRP)和更大的功能损害(BASFI, ASQoL)。外周关节炎(p = 0.001)、胃炎(p = 0.031)、吸烟史(p = 0.037)和合共病(p = 0.020)在D2M-axSpA中更为常见。在D2M-axSpA患者中,22/383(5.7%)符合治疗难治标准。x线检查结果显示骶髂强直、腰椎联合、联合炎和坐骨神经炎的发生率较高,以及mSASSS评分。Logistic回归发现前葡萄膜炎(OR: 4.474, p = 0.007)、周围性关节炎(OR: 2.684, p = 0.021)和合并症(OR: 2.878, p = 0.013)是独立相关因素。结论:研究结果强调了D2M-axSpA的临床和影像学负担,并强调了优化治疗策略的必要性,特别是对于有合并症、有前葡萄膜炎或周围性关节炎史以及有吸烟史的患者。
{"title":"Clinical and Radiographic Factors Associated With Difficult-to-Manage Axial Spondyloarthritis: A Multicenter Study","authors":"Haluk Cinakli,&nbsp;Mete Kara,&nbsp;Gülay Alp","doi":"10.1111/1756-185x.70558","DOIUrl":"10.1111/1756-185x.70558","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the clinical characteristics, disease burden, and treatment patterns of axial spondyloarthritis (axSpA) using the recently proposed Assessment of Spondyloarthritis International Society (ASAS) definition of difficult-to-manage axSpA (D2M-axSpA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 383 patients with axSpA were enrolled. This multicenter cross-sectional study was conducted in three tertiary care centers, enrolling consecutive axSpA patients from outpatient clinics. Patients were classified as D2M-axSpA based on prior use of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and persistent disease activity based on the ASAS definition. Logistic regression analysis identified factors associated with D2M-axSpA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among patients, 11.2% met the D2M-axSpA criteria. The cohort was 58.7% male, with a mean age of 43.5 ± 10.5 years. Radiographic axSpA was present in 70.8%, and 69.2% of patients had received biological therapy. D2M-axSpA patients exhibited higher inflammatory markers (ESR, CRP), increased disease activity (BASDAI, ASDAS-CRP), and greater functional impairment (BASFI, ASQoL). Peripheral arthritis (<i>p</i> = 0.001), enthesitis (<i>p</i> = 0.031), smoking history (<i>p</i> = 0.037), and comorbidities (<i>p</i> = 0.020) were significantly more frequent in D2M-axSpA. Among D2M-axSpA patients, 22/383 (5.7%) fulfilled the treatment-refractory criteria. Radiographic findings revealed higher rates of sacroiliac ankylosis, lumbar syndesmophytes, symphysitis, and ischial enthesitis, as well as mSASSS scores. Logistic regression identified anterior uveitis (OR: 4.474, <i>p</i> = 0.007), peripheral arthritis (OR: 2.684, <i>p</i> = 0.021), and comorbidities (OR: 2.878, <i>p</i> = 0.013) as independently associated factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Findings highlight the clinical and radiographic burden of D2M-axSpA and emphasize the need for optimized treatment strategies, particularly in patients with comorbidities, a history of anterior uveitis or peripheral arthritis, and those with a smoking history.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 2","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146063490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Immune Cells and Plasma Metabolites on Osteoarthritis: A Mediation Mendelian Randomization Study 免疫细胞和血浆代谢物对骨关节炎的影响:一项中介孟德尔随机研究。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-28 DOI: 10.1111/1756-185x.70447
Changfa Huang, Hao Fan, Zhifa Zheng, Wenjing Ma, Ze Wei, Huitian Han, Annan Liang, Xuemeng Mu, Wei Zou, Jing Hao, Fei Liu, Lijin Liu, Su Liu, Lina Zhao, Zhihong Wu

Objective

Recent studies suggest that immune cells and plasma metabolites may play significant roles in osteoarthritis pathogenesis. However, the causal relationships between these factors and osteoarthritis are unclear.

Methods

Based on the genome-wide association study (GWAS) database, 731 immune cell phenotypes and 1400 metabolites were evaluated for their possible mediating effects on osteoarthritis via two-step Mendelian randomization (MR). Sensitivity analyses were conducted to assess the robustness of our findings.

Results

Our findings revealed that 17 immune cell phenotypes were positively associated with osteoarthritis, suggesting their potential as risk factors. Conversely, 23 immune cell phenotypes exhibited a negative association, indicating possible protective roles against osteoarthritis. Furthermore, we identified 51 metabolites as potential risk factors for osteoarthritis. Conversely, 34 metabolites were deemed protective factors. Notably, 49 plasma metabolites partially mediated the relationship between 35 immune cell phenotypes and osteoarthritis, with leucine levels showing the highest mediation proportion (19.3%) between HLA DR+ CD4+ %lymphocytes and osteoarthritis.

Conclusion

Our study revealed a substantial impact of specific immune cell phenotypes and plasma metabolites on the progression of osteoarthritis, enhancing the understanding of the complex interplay between immunity and metabolism in osteoarthritis pathogenesis. Further research is necessary to clarify the underlying mechanisms driving these associations.

目的:最近的研究表明免疫细胞和血浆代谢产物可能在骨关节炎的发病过程中起重要作用。然而,这些因素与骨关节炎之间的因果关系尚不清楚。方法:基于全基因组关联研究(GWAS)数据库,通过两步孟德尔随机化(MR)评估731种免疫细胞表型和1400种代谢物对骨关节炎可能的介导作用。进行敏感性分析以评估我们研究结果的稳健性。结果:我们的研究结果显示17种免疫细胞表型与骨关节炎呈正相关,提示它们可能是危险因素。相反,23种免疫细胞表型表现出负相关,表明可能对骨关节炎具有保护作用。此外,我们确定了51种代谢物作为骨关节炎的潜在危险因素。相反,34种代谢物被认为是保护因素。值得注意的是,49种血浆代谢物部分介导了35种免疫细胞表型与骨关节炎的关系,其中亮氨酸水平在HLA DR+ CD4+ %淋巴细胞与骨关节炎之间的介导比例最高(19.3%)。结论:我们的研究揭示了特异性免疫细胞表型和血浆代谢物对骨关节炎进展的实质性影响,增强了对免疫和代谢在骨关节炎发病机制中的复杂相互作用的理解。需要进一步的研究来阐明驱动这些关联的潜在机制。
{"title":"Effects of Immune Cells and Plasma Metabolites on Osteoarthritis: A Mediation Mendelian Randomization Study","authors":"Changfa Huang,&nbsp;Hao Fan,&nbsp;Zhifa Zheng,&nbsp;Wenjing Ma,&nbsp;Ze Wei,&nbsp;Huitian Han,&nbsp;Annan Liang,&nbsp;Xuemeng Mu,&nbsp;Wei Zou,&nbsp;Jing Hao,&nbsp;Fei Liu,&nbsp;Lijin Liu,&nbsp;Su Liu,&nbsp;Lina Zhao,&nbsp;Zhihong Wu","doi":"10.1111/1756-185x.70447","DOIUrl":"10.1111/1756-185x.70447","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Recent studies suggest that immune cells and plasma metabolites may play significant roles in osteoarthritis pathogenesis. However, the causal relationships between these factors and osteoarthritis are unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Based on the genome-wide association study (GWAS) database, 731 immune cell phenotypes and 1400 metabolites were evaluated for their possible mediating effects on osteoarthritis via two-step Mendelian randomization (MR). Sensitivity analyses were conducted to assess the robustness of our findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our findings revealed that 17 immune cell phenotypes were positively associated with osteoarthritis, suggesting their potential as risk factors. Conversely, 23 immune cell phenotypes exhibited a negative association, indicating possible protective roles against osteoarthritis. Furthermore, we identified 51 metabolites as potential risk factors for osteoarthritis. Conversely, 34 metabolites were deemed protective factors. Notably, 49 plasma metabolites partially mediated the relationship between 35 immune cell phenotypes and osteoarthritis, with leucine levels showing the highest mediation proportion (19.3%) between HLA DR+ CD4+ %lymphocytes and osteoarthritis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study revealed a substantial impact of specific immune cell phenotypes and plasma metabolites on the progression of osteoarthritis, enhancing the understanding of the complex interplay between immunity and metabolism in osteoarthritis pathogenesis. Further research is necessary to clarify the underlying mechanisms driving these associations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 2","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146063604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Report: Acquired Angioneurotic Edema With Massive Pericardial Effusion as the Harbinger of Systemic Lupus Erythematosus 病例报告:获得性血管神经性水肿伴大量心包积液为系统性红斑狼疮的先兆。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-26 DOI: 10.1111/1756-185x.70555
Iwa Bhattarai, Neethu Ravi, Sarthak Chakrabarti, Yash Shrivastava, Prashant Kumar Verma
{"title":"Case Report: Acquired Angioneurotic Edema With Massive Pericardial Effusion as the Harbinger of Systemic Lupus Erythematosus","authors":"Iwa Bhattarai,&nbsp;Neethu Ravi,&nbsp;Sarthak Chakrabarti,&nbsp;Yash Shrivastava,&nbsp;Prashant Kumar Verma","doi":"10.1111/1756-185x.70555","DOIUrl":"10.1111/1756-185x.70555","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay 评论:Get OUT:与急性痛风发作患者住院时间延长相关的因素,以及阿那白对住院时间的影响。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-22 DOI: 10.1111/1756-185x.70556
Selin Cilli Hayıroğlu
{"title":"Comment on: Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay","authors":"Selin Cilli Hayıroğlu","doi":"10.1111/1756-185x.70556","DOIUrl":"10.1111/1756-185x.70556","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation 布西拉胺停药后类风湿因子水平与关节炎恶化相关。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-22 DOI: 10.1111/1756-185x.70551
Yusuke Ogata, Masumi Bamba, Koichi Bamba, Ryo Hisada, Hiroyuki Nakamura

Aim

Bucillamine is a conventional synthetic disease-modifying antirheumatic drug that can be used as a methotrexate alternative. However, which patients with rheumatoid arthritis can benefit from bucillamine treatment has not been established.

Methods

Patients who had taken bucillamine and discontinued it in 2021 due to a nationwide supply shortage were included in this study. We followed up these patients regarding arthritis exacerbation after bucillamine discontinuation until March 2025. Baseline clinical patient characteristics were compared between the exacerbation and non-exacerbation groups.

Results

Thirteen of the 18 patients experienced arthritis exacerbation, whereas five remained exacerbation-free for up to 48 months. The baseline rheumatoid factor levels were significantly higher in the exacerbation group (49 U/mL) than in the non-exacerbation group (6 U/mL). Receiver operating characteristic and Kaplan–Meier analyses showed that baseline RF levels ≥ 28 U/mL predicted arthritis exacerbation after bucillamine discontinuation (sensitivity 76.2% and specificity 80.0%).

Conclusion

Following bucillamine discontinuation, arthritis exacerbations occurred more frequently in patients with rheumatoid factor levels of 28 U/mL or higher, alongside an increase in these levels. Rheumatoid factor levels may serve as a useful biomarker for identifying patients who would benefit from continued bucillamine therapy.

目的:buillamine是一种常规的合成抗风湿药物,可作为甲氨蝶呤的替代品。然而,哪些类风湿性关节炎患者可以从布西胺治疗中获益还没有确定。方法:本研究纳入了因全国供应短缺而于2021年停用布吉拉明的患者。我们在2025年3月之前对这些患者进行了布吉拉明停药后关节炎恶化的随访。比较加重组和非加重组患者的基线临床特征。结果:18名患者中有13名经历了关节炎恶化,而5名患者在长达48个月的时间里没有恶化。基线类风湿因子水平在加重组(49 U/mL)明显高于非加重组(6 U/mL)。受试者工作特征和Kaplan-Meier分析显示,基线RF水平≥28 U/mL预测布吉拉胺停药后关节炎恶化(敏感性76.2%,特异性80.0%)。结论:布吉拉胺停药后,类风湿因子水平为28 U/mL或更高的患者关节炎加重的发生率更高,且类风湿因子水平升高。类风湿因子水平可以作为一种有用的生物标志物,用于识别那些将从布吉拉明治疗中获益的患者。
{"title":"Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation","authors":"Yusuke Ogata,&nbsp;Masumi Bamba,&nbsp;Koichi Bamba,&nbsp;Ryo Hisada,&nbsp;Hiroyuki Nakamura","doi":"10.1111/1756-185x.70551","DOIUrl":"10.1111/1756-185x.70551","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Bucillamine is a conventional synthetic disease-modifying antirheumatic drug that can be used as a methotrexate alternative. However, which patients with rheumatoid arthritis can benefit from bucillamine treatment has not been established.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients who had taken bucillamine and discontinued it in 2021 due to a nationwide supply shortage were included in this study. We followed up these patients regarding arthritis exacerbation after bucillamine discontinuation until March 2025. Baseline clinical patient characteristics were compared between the exacerbation and non-exacerbation groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirteen of the 18 patients experienced arthritis exacerbation, whereas five remained exacerbation-free for up to 48 months. The baseline rheumatoid factor levels were significantly higher in the exacerbation group (49 U/mL) than in the non-exacerbation group (6 U/mL). Receiver operating characteristic and Kaplan–Meier analyses showed that baseline RF levels ≥ 28 U/mL predicted arthritis exacerbation after bucillamine discontinuation (sensitivity 76.2% and specificity 80.0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Following bucillamine discontinuation, arthritis exacerbations occurred more frequently in patients with rheumatoid factor levels of 28 U/mL or higher, alongside an increase in these levels. Rheumatoid factor levels may serve as a useful biomarker for identifying patients who would benefit from continued bucillamine therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “Comparative Effectiveness of TNFα and IL6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study” 修正了“TNFα和IL6抑制剂对类风湿关节炎患者骨健康结局和死亡率的比较有效性:一项回顾性队列研究”。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-22 DOI: 10.1111/1756-185x.70553

Wang H. Lee Y. H. Cheng I.H. Wang S. I. Ji J. Huo A. P. Hung Y.M. 2025 Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study. International Journal of Rheumatic Diseases 28 6 e70204. 10.1111/1756-185X.70204.

The funding section in the above article is incorrect. The correct information is shown below.

Funding

This work was supported by funding from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University (CSH-2024-E-001-Y2) and Zhejiang Provincial Natural Science Foundation of China (LGJ21H100001).

We apologize for this error.

王慧,李彦宏,郑志宏,王淑娟,季军,霍爱萍,洪彦明。2025类风湿性关节炎患者骨健康结局和死亡率的TNF-α和IL-6抑制剂的比较疗效:回顾性队列研究。国际风湿病杂志28 6 e704。10.1111 / 1756 - 185 x.70204。上述文章中的资金部分是不正确的。正确的信息如下所示。本研究由温州医科大学附属第二医院、育婴儿童医院(编号:CSH-2024-E-001-Y2)和浙江省自然科学基金(编号:LGJ21H100001)资助。我们为这个错误道歉。
{"title":"Correction to “Comparative Effectiveness of TNFα and IL6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study”","authors":"","doi":"10.1111/1756-185x.70553","DOIUrl":"10.1111/1756-185x.70553","url":null,"abstract":"<p>Wang H. Lee Y. H. Cheng I.H. Wang S. I. Ji J. Huo A. P. Hung Y.M. 2025 Comparative Effectiveness of TNF-α and IL-6 Inhibitors on Bone Health Outcomes and Mortality in Rheumatoid Arthritis Patients: A Retrospective Cohort Study. International Journal of Rheumatic Diseases 28 6 e70204. 10.1111/1756-185X.70204.</p><p>The funding section in the above article is incorrect. The correct information is shown below.</p><p>\u0000 <b>Funding</b>\u0000 </p><p>This work was supported by funding from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University (CSH-2024-E-001-Y2) and Zhejiang Provincial Natural Science Foundation of China (LGJ21H100001).</p><p>We apologize for this error.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185x.70553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robotic Ultrasound-Guided Musculoskeletal Injections: The Next Frontier in Precision Medicine 机器人超声引导肌肉骨骼注射:精准医学的下一个前沿。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-21 DOI: 10.1111/1756-185x.70557
Ahmad Jasem Abdulsalam, Renu Ambardar, Sarah Y. Alkandari
{"title":"Robotic Ultrasound-Guided Musculoskeletal Injections: The Next Frontier in Precision Medicine","authors":"Ahmad Jasem Abdulsalam,&nbsp;Renu Ambardar,&nbsp;Sarah Y. Alkandari","doi":"10.1111/1756-185x.70557","DOIUrl":"10.1111/1756-185x.70557","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent Erythema and Induration of the Upper Arm in a Young Woman: What Is the Cause? 年轻女性上臂复发性红斑和硬结:原因是什么?
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-21 DOI: 10.1111/1756-185x.70554
Susumu Tsunoda, Naoki Sawa
{"title":"Recurrent Erythema and Induration of the Upper Arm in a Young Woman: What Is the Cause?","authors":"Susumu Tsunoda,&nbsp;Naoki Sawa","doi":"10.1111/1756-185x.70554","DOIUrl":"10.1111/1756-185x.70554","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomechanics and Obesity in Osteoarthritis: From Mechanism to Precision Medicine 骨关节炎的生物力学与肥胖:从机制到精准医学。
IF 2 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2026-01-21 DOI: 10.1111/1756-185x.70539
Shangqi Guan, Yifang Mei

Osteoarthritis (OA) is a degenerative joint disease driven by complex biomechanical and inflammatory mechanisms, particularly in weight-bearing joints such as the knee. This review explores the pivotal role of biomechanics in OA pathogenesis, focusing on abnormal joint loading, malalignment, and instability as key contributors to cartilage degeneration and subchondral bone remodeling. Special attention is given to the interplay between obesity and OA, highlighting how mechanical overload and adipokine-mediated inflammation synergistically accelerate disease progression. Emerging interventions—including physical therapy, gait retraining, orthotics, high tibial osteotomy (HTO), and total knee arthroplasty (TKA)—are analyzed for their biomechanical impact. Novel technologies such as wearable sensors, finite element analysis (FEA), and digital twin models are discussed as tools for real-time assessment, predictive modeling, and personalized treatment planning. The review emphasizes the need for integrated, multiscale research strategies that account for individual biomechanical profiles and systemic factors like obesity. Advancing biomechanical precision in OA management holds promise for improving early diagnosis, optimizing interventions, and informing regenerative therapies aimed at restoring joint function and delaying disease progression.

骨关节炎(OA)是一种由复杂的生物力学和炎症机制驱动的退行性关节疾病,特别是在负重关节,如膝关节。这篇综述探讨了生物力学在OA发病机制中的关键作用,重点讨论了异常关节负荷、错位和不稳定是软骨退变和软骨下骨重塑的关键因素。特别关注肥胖和OA之间的相互作用,强调机械负荷和脂肪因子介导的炎症如何协同加速疾病进展。新出现的干预措施——包括物理治疗、步态再训练、矫形器、胫骨高位截骨术(HTO)和全膝关节置换术(TKA)——分析了它们的生物力学影响。新技术,如可穿戴传感器、有限元分析(FEA)和数字孪生模型作为实时评估、预测建模和个性化治疗计划的工具进行了讨论。该综述强调需要综合、多尺度的研究策略,以考虑个体生物力学特征和肥胖等系统性因素。提高骨性关节炎管理的生物力学精度有望改善早期诊断,优化干预措施,并为旨在恢复关节功能和延缓疾病进展的再生疗法提供信息。
{"title":"Biomechanics and Obesity in Osteoarthritis: From Mechanism to Precision Medicine","authors":"Shangqi Guan,&nbsp;Yifang Mei","doi":"10.1111/1756-185x.70539","DOIUrl":"10.1111/1756-185x.70539","url":null,"abstract":"<div>\u0000 \u0000 <p>Osteoarthritis (OA) is a degenerative joint disease driven by complex biomechanical and inflammatory mechanisms, particularly in weight-bearing joints such as the knee. This review explores the pivotal role of biomechanics in OA pathogenesis, focusing on abnormal joint loading, malalignment, and instability as key contributors to cartilage degeneration and subchondral bone remodeling. Special attention is given to the interplay between obesity and OA, highlighting how mechanical overload and adipokine-mediated inflammation synergistically accelerate disease progression. Emerging interventions—including physical therapy, gait retraining, orthotics, high tibial osteotomy (HTO), and total knee arthroplasty (TKA)—are analyzed for their biomechanical impact. Novel technologies such as wearable sensors, finite element analysis (FEA), and digital twin models are discussed as tools for real-time assessment, predictive modeling, and personalized treatment planning. The review emphasizes the need for integrated, multiscale research strategies that account for individual biomechanical profiles and systemic factors like obesity. Advancing biomechanical precision in OA management holds promise for improving early diagnosis, optimizing interventions, and informing regenerative therapies aimed at restoring joint function and delaying disease progression.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"29 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Rheumatic Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1